Nutraceuticals for the prevention of liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD)
Food Science and Biotechnology · 2026-12 · 35 (14) · 3925-3936
DOI: 10.1007/s10068-026-02236-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Food Science and Biotechnology, online erschienen am 15.07.2026. Verfasst von Muhammad Yasir Naeem und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Agronomy, Food, Natural Resources, Animals and Environment (DAFNAE), University of Padova, Padua, Italy. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) can progress to metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis, a condition driven by chronic inflammation, oxidative stress, and excessive extracellular matrix deposition. The progression of fibrosis to cirrhosis or hepatocellular carcinoma, coupled with limited treatment options, necessitates new therapeutic strategies. This review describes the protective role of nutraceuticals against liver fibrosis in MASLD, focusing on their anti-inflammatory, antioxidant, and direct anti-fibrotic properties. We examine the evidence for specific nutraceuticals including polyphenols (resveratrol, curcumin), omega-3 fatty acids, vitamin E, and their efficacy in modulating key pathways of fibrogenesis, particularly the activation of hepatic stellate cells. We conclude that nutraceuticals offer a promising, multifaceted approach to liver protection by targeting underlying metabolic dysregulation and the core drivers of fibrotic scarring.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Agronomy, Food, Natural Resources, Animals and Environment (DAFNAE), University of Padova, Padua, Italy.
- Department of Clinical and Molecular Medicine, University of Palermo, Palermo, Italy.
ORCID-Profile: Muhammad Yasir Naeem
Zitieren
APA
Naeem, M. Y., & Ijaz, T. (2026). Nutraceuticals for the prevention of liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD). Food Science and Biotechnology, 35(14), 3925-3936. https://doi.org/10.1007/s10068-026-02236-3
Vancouver
Naeem MY, Ijaz T. Nutraceuticals for the prevention of liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD). Food Science and Biotechnology. 2026;35(14):3925-3936. doi:10.1007/s10068-026-02236-3
BibTeX
@article{Naeem2026,
author = {Naeem, Muhammad Yasir and Ijaz, Tabinda},
title = {Nutraceuticals for the prevention of liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD)},
journal = {Food Science and Biotechnology},
year = {2026},
volume = {35},
number = {14},
pages = {3925--3936},
doi = {10.1007/s10068-026-02236-3}
}
EUVIMED